TABLE 1.
Variable | Placebo | Sitagliptin | P-value |
---|---|---|---|
Number of participants | 91 | 91 | |
Gender | .24 | ||
Male | 70 (77) | 63 (69) | |
Female | 21 (23) | 18 (31) | |
Age, years | 64 ± 9 | 63 ± 8 | .48 |
Race | .92 | ||
Caucasian | 68 (75) | 67 (74) | |
African American | 19 (21) | 21 (23) | |
Other | 4(4) | 3(3) | |
Body weight, kg | 97 ± 21 | 96 ± 19 | .96 |
BMI, kg/m2 | 32 ± 7 | 32 ± 6 | .34 |
Diabetes history | |||
Diabetes duration, years | 9±7 | 12 ± 10 | .18 |
Outpatient diabetes therapy | .32 | ||
None | 7 (8) | 2 (2) | |
Diet only | 5 (5) | 3 (3) | |
OAD only | 52 (57) | 63 (69) | |
DPP-4 inhibitors | 11 (17) | 20 (27) | |
Metformin | 62 (89) | 66 (81) | |
Sulphonylureas | 18 (28) | 24 (32) | |
Thiazolinediones | 0(0) | 6 (8) | |
SGLT-2 | 7 (14) | 5 (8) | |
OAD + insulin | 17 (19) | 15 (16) | |
GLP-1 | 0 (0) | 2 (2) | |
GLP-1 + OAD | 2 (2) | 2 (2) | |
Insulin only | 7 (8) | 3 (3) | |
Home total insulin dose, units | 50.3 ± 34.4 | 57.1 ± 50.4 | .95 |
Total insulin dose adjusted by weight | 0.49 ± 0.33 | 0.61 ± 0.51 | .37 |
Type of surgery | .54 | ||
Elective/outpatient | 53 (59) | 49 (54) | |
Emergent | 5(6) | 10 (11) | |
Transfer from another hospital | 7(8) | 5 (5) | |
Urgent | 25 (28) | 27 (30) | |
Type of CABG procedure | .65 | ||
Open CABG | 76 (84) | 79 (87) | |
Robotic CABG | 14 (16) | 12 (13) | |
Length of surgery (minutes) | 311 ± 90 | 310 ± 93 | .85 |
Number of vessels, median (Q1, Q3) | 3.0 [2.0, 4.0] | 3.0 [2.0,3.0] | .89 |
ASA | .83 | ||
III | 12 (13) | 14 (15) | |
IV | 77 (86) | 77 (85) | |
V | 1(1) | 0 (0) |
Abbreviations: ASA, American Society of Anaesthesiology; BMI, body mass index; CABG, coronary artery bypass graft surgery; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; ICU, intensive care unit; OAD, oral antidiabetic drug; SGLT-2, sodium-glucose co-transporter-2.
Data are n (%), mean ± standard deviation, or median [IQR]; IQR, interquartile range.